Key Highlights

  • bioAffinity regained compliance with Nasdaq's $1.00 minimum bid-price requirement following a 1-for-15 reverse split effective August 24, 2026.
  • The company announced a federal distribution Partnership with AvMEDICAL to commercialize CyPath Lung across U.S. government healthcare systems.
  • Second-quarter 2026 Revenue was about $1.51 million, up roughly 19% year over year, with a narrower net loss of about $3.37 million.

bioAffinity Technologies, Inc (NASDAQ: BIAF) has staged a sharp single-session rally, climbing roughly 18%, at a moment when the small diagnostics company is stitching together a run of corporate milestones. After a 1-for-15 Reverse Stock Split in August and a fresh confirmation that it has regained compliance with Nasdaq's listing rules, the low-float stock is capable of dramatic swings. The question the market is weighing is whether recent developments mark the start of durable momentum or simply Volatility in a heavily reduced share count.

Company and Latest Development

San Antonio, Texas-based bioAffinity Technologies develops non-invasive diagnostics for early-stage lung cancer, led by CyPath Lung, a test that applies flow cytometry to sputum samples to help assess cancer risk. On September 9, 2026, the company said it had regained compliance with Nasdaq's minimum $1.00 bid-price requirement, following a 1-for-15 reverse split that took effect on August 24. In the weeks prior, bioAffinity announced a federal distribution partnership with AvMEDICAL to commercialize CyPath Lung across U.S. government healthcare systems and outlined an expansion of the test toward post-treatment surveillance for lung cancer survivors.

What Is Driving Attention Around BIAF?

The timing of the roughly 18% advance is notable: it coincided with the September 9 announcement that the company had cured its Nasdaq bid-price deficiency, a development that removes a near-term delisting overhang and can improve sentiment. Still, caution is warranted in attributing the entire move to that single item. Following the reverse split, bioAffinity's public float is very small, and low-float micro-caps routinely post outsized percentage moves on modest volume. The recent string of positive announcements, compliance, the AvMEDICAL deal and the surveillance expansion, provides a supportive backdrop, but the precise driver of any one session's move is difficult to pin down.

Key Numbers and Company Position

For the second quarter of 2026, bioAffinity reported revenue of about $1.51 million, up roughly 19% year over year, with CyPath test Volume rising sharply, and a narrower net loss of about $3.37 million. In mid-August the company raised approximately $4 million through an at-the-market-priced Warrant offering. After the 1-for-15 reverse split, shares outstanding fell to a fraction of prior levels, and the stock recently traded around $10.50, giving bioAffinity a market Capitalization of only about $6 million. The split-adjusted 52-week range is extremely wide, reflecting the stock's steep prior decline.

What Could Come Next?

Commercial traction for CyPath Lung is the central variable. Investors will watch for execution on the AvMEDICAL federal distribution agreement, uptake in the post-treatment surveillance segment the company has flagged, and continued growth in test volumes and revenue. bioAffinity was slated to present at the H.C. Wainwright Global Investment Conference in mid-September, and future quarterly results, reimbursement progress and any additional financing will be closely followed.

Risks to Watch

The risks are considerable. bioAffinity is a pre-profitability micro-cap with a small revenue base and recurring net losses, and its recent capital raise underscores ongoing funding needs that could lead to further dilution. Having only just regained compliance after a reverse split, the company must sustain its share price and financial metrics to avoid future listing issues. Diagnostics adoption depends on clinical validation, reimbursement and physician uptake, all of which take time. The very low float that can drive rapid rallies can also drive steep declines.

Conclusion

bioAffinity Technologies has paired a headline-grabbing rally with a genuine cluster of milestones: a Nasdaq compliance recovery, a federal distribution partnership and an expanding use case for CyPath Lung. Yet the company remains a tiny, loss-making diagnostics developer whose reduced float amplifies price swings in both directions. Whether BIAF is building fresh momentum will hinge on commercial execution and its ability to convert partnerships into sustained revenue growth, the developments investors may most want to monitor in the months ahead.